^
    9ms
    ⁦@US_FDA⁩ ‘s Withdrawal of Later-Line Indication For #Olaparib in #BRCA Mutated #OvarianCancer ⁦@OncLive⁩ #gyncsm #womenshealth #cancerresearch #PARP https://t.co/MY9RghtCLp (@LguzzardiM)
    BRCA (Breast cancer early onset) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
    |
    BRCA mutation
    |
    Lynparza (olaparib)
    9ms
    The addition of Talazoparib(PARPi) to enzalutamide in CRPC has most marked effects in BRCA+ve tumors. Effects in the remaining HRR population are marginal. This is largely consistent with previous data for PARPi in CRPC, supporting the ODAC decision on olaparib #ACScancerchat (@tompowles1)
    ODAC
    |
    BRCA (Breast cancer early onset)
    |
    Lynparza (olaparib) • Talzenna (talazoparib) • Xtandi (enzalutamide capsule)
    9ms
    Olaparib 💊 for neoadjuvant treatment of ovarian cancer!? In this podcast @ShannonWestin discusses with @pedroramirezMD the NOW trial 💥 📌https://t.co/5i99X3tfl4 @IJGConline @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @IJGCfellows @GynMe4 (@GuidoReyv)
    Clinical
    |
    Lynparza (olaparib)
    10ms
    🎥@AarmstrongDuke of @DukeCancer shares exciting findings from PROpel trial in mCRPC: Abiraterone + Olaparib shows improved rPFS without impacting HRQoL: ➡️https://t.co/7p9FFyoogR #PCSM #UroOnc #ASCO2023 @ASCO (@VJOncology)
    Lynparza (olaparib) • abiraterone acetate
    10ms
    NRG-GY012 Study Tests Multiple Olaparib Combinations in Endometrial Cancer https://t.co/iA3GZYAvc7 via @targetedonc (@NCCH_MD)
    Lynparza (olaparib)
    10ms
    Exciting news in #mCRPC research! Join @CaPsurvivorship @DanaFarber and Fred Saad, MD, FRCS @chumontreal as they discuss the #PROpel trial's final OS data, showing a 7.4-month improvement in pts who received abiraterone and olaparib. #WatchNow > https://t.co/WTPVLZ4Wa5 (@urotoday)
    Clinical
    |
    Lynparza (olaparib) • abiraterone acetate
    10ms
    🎥@vanderweelemd shares findings on DDR and PARP inhibition in prostate cancer: BRCA1/2 and HRR genes are vital prognostic biomarkers, TALAPRO-2 trial strengthens BRCA1/2 as predictive markers, LuPARP trial demonstrates olaparib's safety in mCRPC https://t.co/Qsi0Ac26ZF #ASCO23 (@VJOncology)
    Clinical
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    Lynparza (olaparib)
    10ms
    I agree!! If access is not an issue, I would continue Pembro in adjuvant setting along with 6-8 cycles of capecitabine and RT if needed, followed by Olaparib for high risk TNBC with residual disease! (@killthecancer)
    Clinical
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • capecitabine
    11ms
    New #ETCTN #solidtumor #clinicaltrial: (10551) “A Phase I/Ib Study of Anti-CD47 Hu5F9-G4 (Magrolimab) in Combination With Olaparib in Patients With BRCA1/2-Mutant Tumors”, led by @HaiderMahdiMD of @UPMCHillmanCC. Learn more about this #CancerResearch: https://t.co/kzCT7a7Zuf (@NCICTEP_ClinRes)
    Clinical • Combination therapy
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • magrolimab (GS-4721)
    11ms
    Now in @JCO_ASCO ➡️ KEYLYNK-010 trial: Pembro + Olaparib vs 2nd NHA in mCR #prostatecancer (https://t.co/Owpcfb6XS0) ➡️ Despite promising early phase data, no diff. in rPFS or OS j ➡️ My take: outside of selected biomarker groups (MSI-high, CDK12?), no role for ICI in PCa (@AzadOncology)
    CDK12 (Cyclin dependent kinase 12)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib)
    11ms
    Exciting news in #mCRPC research! Join @CaPsurvivorship @DanaFarber and Fred Saad, MD, FRCS @chumontreal as they discuss the #PROpel trial's final OS data, showing a 7.4-month improvement in pts who received abiraterone and olaparib. #WatchNow > https://t.co/WTPVLZ4Wa5 (@urotoday)
    Clinical
    |
    Lynparza (olaparib) • abiraterone acetate
    11ms
    Congratulations to @EliasChandran, our advanced GU oncology fellow at @theNCI working with @apolo_andrea, for two poster presentations at ASCO 2023: dMMR and MSI-H in urothelial carcinoma and trial in progress of olaparib in non-prostate GU tumors (NCT03375307) #ASCO2023 @ASCO (@NCICCR_MOS)
    Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Lynparza (olaparib)
    11ms
    “Phase ll clinical trial of olaparib plus pembrolizumab in the treatment of patients with advanced biliary tract cancer.” Research by James O’Bryan, @ChYin89, @mnoel3232, @ReetuMukherjiMD, @MarionHartley4, @marshalj23, @RuthHe12 and others @LombardiCancer. Poster #408 #ASCO23 (@RueschCenter)
    Clinical • Metastases
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib)
    11ms
    “A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant #prostate cancer with bone metastases (COMRADE): A trial in progress.” at #ASCO23 @ASCO (@RutgersCancer)
    P1/2 data
    |
    Lynparza (olaparib) • Xofigo (radium Ra-223 dichloride)
    11ms
    @Dr_RaviMadan …sadly missing #ASCO23 this year, so can’t ask you in person…but what would you do with BRCA2 1L (ARSI naive) mCRPC patient with new FDA approval?…combo or olaparib>abi, or abi>olaparib (let’s say you can get these through insurance) 🤔🤔 (@RPachynski)
    Clinical • FDA event • Reimbursement • US reimbursement
    |
    BRCA2 (Breast cancer 2, early onset)
    |
    Lynparza (olaparib)
    11ms
    Health-related quality of life and pain outcomes for patients with #mCRPC who received abiraterone and olaparib vs Abi and placebo in the phase III #PROpel trial. Presented by @AarmstrongDuke @DukeCancer. #ASCO23 written coverage by @RKSayyid @UofT > https://t.co/Fm46a2XSJE @ASCO (@urotoday)
    Clinical • HEOR
    |
    Lynparza (olaparib) • abiraterone acetate
    11ms
    LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer. ☢️No G4 AEs or DLT 🧬PSA50 response % 66 ☢️ ORR is 78% ☢️Promising but need to see comparative study! @ASCO @OncoAlert #ASCO23 @sophia_kamran @FatimaKarzai… https://t.co/7aMd2o7MB7 (@DrYukselUrun)
    Clinical • Metastases
    |
    Lynparza (olaparib) • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    11ms
    We have a fantastic team of rising ⭐️s @EliasChandran @GMIannantuonoMD @NicholasISimon @NCIResearchCtr presenting our #BladderCancer posters on 1]mismatch repair deficiency & MSI 2]Olaparib biomarker-selected TPS 3]M7824 +NHS-IL12 +/-XRT study 4] AI with PET/CT @ASCO #ASCO23 https://t.co/hC7whE1DIR (@apolo_andrea)
    Mismatch repair
    |
    Lynparza (olaparib) • bintrafusp alfa (M7824) • PDS01ADC
    11ms
    @SandhuShahneen presenting very intriguing data on the phase 1 combination of Lu-PSMA and Parp Inhibitor Olaparib. Amazing PSA90 of 44% and ORR of 78%. Intermittent dosing likely will be more tolerable for our patients. Hopefully more to come! #ASCO2023 #pcsm - @BGarmezy (@OncLive)
    Clinical • P1 data
    |
    Lynparza (olaparib)
    11ms
    Thank you, @urotoday, for the excellent coverage of the #COMRADE trial at #ASCO23! I'm honored to have presented the study under mentoship of @DrRanaMcKay on the combination of olaparib and radium-223 for men with #mCRPC and bone metastases. #ProstateCancer @MAHIMRes @harvardmed (@Jani_Chinmay)
    Lynparza (olaparib) • Xofigo (radium Ra-223 dichloride)
    11ms
    Having a great time at #ASCO2023 with mentor @EAntonarakis presenting work on olaparib mono therapy in prostate cancer on behalf of (@CathyHandy)
    Lynparza (olaparib)
    11ms
    Results show that durvalumab plus olaparib added to standard care improves PFS in newly diagnosed advanced #ovariancancer w/out BRCA mutation. Findings were introduced in an #ASCO23 news briefing. @DrMarkham of @UFMedicine shares insights. #onctwitter https://t.co/sfEx1ErEbz (@OBRtweets)
    Metastases
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab)
    11ms
    @Dr_RaviMadan: CHAARTED 3-mo landmark #QOL prognostic of OS in #mHSPC, PhIII TALAPRO-2 w/o clin meaningful deterior w/tala + enza vs enza in #1L mCRPC, PROPEL 8 mo delay in time to chemo w/Abi + olaparib vs Abi alone in #1L #mCRPC how much driven by #BRCA mt? #ASCO23 @OncoAlert (@jgong15)
    BRCA (Breast cancer early onset)
    |
    Lynparza (olaparib)
    11ms
    Proof of principal that some HRR+ prostate cancer pts have an at least partially AR-independent disaese. Phase II study of olaparib mono therapy in BCR by @EAntonarakis @JohnsHopkins @ASCO @OncoAlert @mtsiatas #ASCO23 (@MichalisLiontos)
    Clinical • P2 data
    |
    Lynparza (olaparib)
    11ms
    Dr. @AarmstrongDuke with a poster discussion on HRQoL and pain outcomes for patients with mCPRC treated with abiraterone + olaparib from the PROpel trial at #ASCO23! Starting at 1:15pm in E450. #ProstateCancer #mCPRC @AstraZeneca (@IDEOlogyHealth)
    Clinical
    |
    Lynparza (olaparib) • abiraterone acetate
    11ms
    On May 31, the @US_FDA approved olaparib plus abiraterone and prednisone or prednisolone in adult patients with mCRPC with BRCA mutations based on findings from the PROpel trial (NCT03732820). Dr. @AarmstrongDuke @DukeGUCancer weighs in. (@DukeCancer)
    Clinical • FDA event
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • abiraterone acetate
    11ms
    LYNPARZA® (olaparib) + abiraterone approved in the US for the treatment of BRCA-mutated #mCRPC. Approval based on a subgroup analysis of the PIII #PROpel trial #ReadNow details on UroToday > https://t.co/dZpX6CTT9E @AstraZeneca @Merck @AarmstrongDuke @LYNPARZAhcp @FoundationATCG (@urotoday)
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • abiraterone acetate
    11ms
    WATCH: @AarmstrongDuke, of @DukeCancer, discusses the significance of the FDA approval of olaparib plus abiraterone acetate and prednisone or prednisolone in patients with BRCA-mutated metastatic castration-resistant prostate cancer. #pcsm https://t.co/DpJtToQdQ0 (@OncLive)
    Clinical • FDA event • Metastases
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • abiraterone acetate
    11ms
    WATCH: Dr Armstrong on the FDA Approval of Abiraterone/Olaparib Combination in BRCA-mutated mCRPC @AarmstrongDuke @DukeCancer @US_FDA #pcsm https://t.co/m0KuRlI4JO (@OncLive)
    FDA event
    |
    BRCA (Breast cancer early onset) • RMST (Rhabdomyosarcoma 2 Associated Transcript)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • abiraterone acetate
    11ms
    #1 - @brian_rini discussing long-term f/u of pembo+axi in 1L mRCC #2 - @AarmstrongDuke discussing the role of AI-based biomarker to guide ADT rx in men receiving RT for HR-PCa and HRQoL in 1L mCRPC with olaparib+abi (@WallisCJD)
    Lynparza (olaparib)
    11ms
    FDA Approves Olaparib Triplet for mCRPC https://t.co/rsDVALesEy via @targetedonc (@DrBonillaOnc)
    FDA event
    |
    Lynparza (olaparib)
    11ms
    FDA Approves Olaparib Triplet for mCRPC https://t.co/jty4P6r6oH vía @targetedonc (@DrMedOnco)
    FDA event
    |
    Lynparza (olaparib)
    11ms
    And it’s finally out: FDA just approves olaparib+abiraterone for mCRPC pra with BRCA mut. #propel f/ ODAC recs. More news with #talapro2 #magnitude soon @FDAOncology ? @neerajaiims @AarmstrongDuke @DrChoueiri @GUONCGarciaJA @AarmstrongDuke @DrRanaMcKay https://t.co/0cmIbKj5ud (@PBarataMD)
    FDA event • ODAC
    |
    BRCA (Breast cancer early onset)
    |
    Lynparza (olaparib) • abiraterone acetate
    11ms
    After #ODAC of #PROpel trial, @FDAOncology approves Olaparib + ABI + PDN for pts w/ #BRCAm #mCRPC ✅ rPFS HR 0.24 ✅ OS HR 0.30 🧐 AE: anemia, fatigue, DVT + sympts during first 3C Approval based on 11% of ITT 😯 To discuss in #ASCO2023 https://t.co/3uMdKkX8tw @OncoAlert (@TapiaJC1)
    Clinical • ODAC
    |
    Lynparza (olaparib)
    11ms
    Breaking news👉@FDAoncology approves the combo of abiraterone+Olaparib for mCRPC #prostatecancer with BRCA1 & BRCA2 mutations. Weblink: https://t.co/uU9MQs81Xs @ONCOALERT @PCFnews @urotoday @DrChoueiri @ZEROCancer @CancerDotNet #ASCO23 @ASCO (@neerajaiims)
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation
    |
    Lynparza (olaparib) • abiraterone acetate
    11ms
    #ASCO23 @ASCO Abs#8518 TRIDENT: Durva + olaparib maint tx following durva + carbo + etop in Ext Stage #SCLC ➡️ Single Arm, Phase II Study ➡️ ORR 75% ➡️ Median DoR ~ 5.0 mo ➡️ Median PFS ~ 5.8 months ➡️Median OS NR https://t.co/PzPa7tLy1A @OncoAlert @HemOncToday (@CharuAggarwalMD)
    Lynparza (olaparib)
    11ms
    A phase II basket trial shows an antitumor activity for olaparib in metastatic castrate-resistant prostate cancer and BRCA1/2 mutations https://t.co/yCdmhZTCJT #fondazionebonadonna #CancerResearch #oncology @BianchiniGP @CarmenCriscit @mauricallari (@FondazioneBona1)
    Pan tumor • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib)
    11ms
    Durvalumab + platinum-based chemotherapy, followed by maintenance therapy w/ either durvalumab + olaparib or durvalumab alone, elicited an improvement in PFS in newly diagnosed, advanced/ recurrent endometrial cancer. @ShannonWestin @MDAndersonNews #gyncsm https://t.co/WvbJWMscfQ (@OncLive)
    Clinical • Metastases
    |
    Lynparza (olaparib) • Imfinzi (durvalumab)
    11ms
    Durvalumab + platinum-based chemotherapy, followed by maintenance therapy w/ either durvalumab + olaparib or durvalumab alone, elicited an improvement in PFS in newly diagnosed, advanced/ recurrent endometrial cancer. @ShannonWestin @MDAndersonNews #gyncsm https://t.co/PCR62rkQir (@OncLive)
    Clinical • Metastases
    |
    Lynparza (olaparib) • Imfinzi (durvalumab)
    11ms
    @ASCO is coming up next week! @MirzaCPH will present: A randomized trial of olaparib, durvalumab, and #cancervaccine, UV1, as maintenance therapy in patients with BRCAwt with recurrent #ovariancancer: ENGOT-OV56/NSGO-CTU-DOVACC trial #phase2 #immunotherapy https://t.co/9YWK7m4cHZ (@ultimovacs)
    Clinical
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • UV1
    11ms
    Durvalumab Plus Chemotherapy With or Without Olaparib Improves PFS in Advanced Endometrial Cancer https://t.co/Js2OhmTijy vía @onclive (@DrMedOnco)
    Metastases
    |
    Lynparza (olaparib) • Imfinzi (durvalumab)
    11ms
    Durvalumab Plus Chemotherapy With or Without Olaparib Improves PFS in Advanced Endometrial Cancer @ShannonWestin @MDAndersonNews #gyncsm https://t.co/6uLrdfm4d5 (@OncLive)
    Metastases
    |
    Lynparza (olaparib) • Imfinzi (durvalumab)